Rosanna Sutherby, Pharm.D.

The out-of-pocket cost for MS disease-modifying therapies jump by 217% going from $750 per year in 2012 to $2,378 per year in 2021.

10 treatments are listed as first-line advanced therapies. Rinvoq (upadacitinib) is the only one with a clinically meaningful difference from placebo of over 20%.

The investigational Bruton’s tyrosine kinase performed well in the phase 3 HERCULES trial.

People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.

Researchers say patient-reported disability can be used as a metric in outcomes-based contracts related to the care of multiple sclerosis patients.

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal complications among those treated with semaglutide, tirzepatide and other GLP-1s.

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative conditions

Research might produce treatments of involving transplants with a few, selected types of bacteria tailored to an individual's microbiome.

But three — tolebrutinib, fenebrutinib, and remibrutinib — are now in late-stage trials.

One of the projects involves,studying a type of cholesterol that may promote myelin repair.

The results showed that 26% of patients who received tulisokibart achieved clinical remission at week 12 compared with 1% of those who received placebo.

Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis factor blocker, resulted in the lowest overall incidence of adverse events, according to an industry-sponsored study.

Results of a survey show that Black/Indigenous/People of Color or Hispanic patients with Crohn's disease or ulcerative colitis were more likely to report poor symptom control and greater difficulty accessing care from specialists and twice as likely to have an IBD-related emergency department visit compared with White non-Hispanic patients.

Segesterone acetate is a laboratory-made derivative of progesterone, a sex hormone used in many hormonal contraceptives

Study eases some of the concern about Crohn's disease and ulcerative colitis creating undue infection risk.

Roche's drug is one of a number competing to become the first Bruton's kinase inhibitors approved as a treatment for multiple sclerosis.

Entyvio (vedolizumab) and Xeljanz (tofacitinib) are the most commonly studied therapies, according to the Pfizer-sponsored review, and when the two were compared, Xeljanz showed higher remission rates.

A positive result for Bruton’s tyrosine kinase inhibitor after the drug had been put on partial clinical hold due to concerns about liver toxicity.

The emergence of biologics and other disease-modifying therapies for UC has changed the face of UC treatment in the last 20 years. However, although the number is decreasing, up to 15% of patients with UC will still require colectomy surgery during their lifetime.

Research has observed a decreased risk of autoimmune disorders, including MS, in people who consume alcohol. However, it is not known whether patients may reduce their alcohol consumption as their disease progresses.

According to a study, increased competition brought about by the emergence of biosimilars in the market has resulted in a CAGR decrease of 5% to 20% in biosimilar and reference product pricing. It is estimated that biosimilars have saved payers, and in the end patients, more than $100 billion over five years.

In a recent study, the investigational drug, PIPE-307, effectively induced OPC differentiation and remyelination in MS donor human brain tissue and an animal model and restored lost function in an MS mouse model.

Intranasal administration is a novel delivery method for the treatment of inflammatory human diseases.

Researchers say depictions of inflammatory bowel disease (IBD). which includes ulcerative colitis, don't reflect the growing the incidence of IBD in older and nonwhite populations.

If approved by the FDA they would join Trodelvy as a treatment for triple-negative breast cancer.

The FDA may approve KarXT, an antipsychotic that does not have the side effects of some other antipsychotics because it does not affect dopamine receptors.

In one key finding of the study, about half of the healthcare professionals listed bowel urgency as one of the top five symptoms that impact patients’ lives, however, only about a quarter of them ranked it as a top three symptom affecting treatment decisions.